-
公开(公告)号:US11584737B2
公开(公告)日:2023-02-21
申请号:US17042394
申请日:2019-03-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Koji Ono , Masahiro Ito , Toshio Tanaka , Moriteru Asano , Takaharu Hirayama , Jun Fujimoto , Nobuki Sakauchi , Yasuhiro Hirata , Akinori Toita , Nao Morishita , Hironori Kokubo , Yasuhiro Imaeda , Hironobu Maezaki , Douglas Robert Cary , Ryo Mizojiri , Nobuo Cho , Hiroshi Banno , Hidekazu Tokuhara , Yasuyoshi Arikawa
IPC: C07D401/14 , C07D403/14 , A61P35/00 , C07D213/84 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/10 , C07D487/10 , C07D495/10
Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US10696651B2
公开(公告)日:2020-06-30
申请号:US16323863
申请日:2017-08-09
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Jun Fujimoto , Xin Liu , Osamu Kurasawa , Terufumi Takagi , Douglas Robert Cary , Hiroshi Banno , Yasutomi Asano , Takuto Kojima
IPC: C07D401/12 , C07D403/12 , C07D401/14 , C07D213/75 , C07D405/12 , C07D239/42 , C07D241/12 , C07D471/04 , C07D498/04 , C07D213/65 , A61P35/00 , C07D241/20 , C07D213/73 , A61K31/53 , A61K31/505 , A61K31/4406 , A61K31/444 , A61K31/4965 , C07D213/68 , C07D213/42 , A61K31/506 , A61K31/497 , A61K31/4375 , C07D239/20 , A61P43/00 , A61K31/5383 , A61K31/437 , A61K31/44 , C07D253/06 , C07D231/12 , C07D239/30 , C07D239/34 , C07D239/48 , C07D253/07 , C07D409/12 , C07D487/04
Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US09957251B2
公开(公告)日:2018-05-01
申请号:US15304623
申请日:2015-04-16
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takaharu Hirayama , Jun Fujimoto , Douglas Robert Cary , Masanori Okaniwa , Yasuhiro Hirata
IPC: C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D491/08 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4704 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/499 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/553 , C07D409/04 , C07D409/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/107 , C07D498/08 , C07D213/64
CPC classification number: C07D401/04 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4704 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/499 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/553 , C07D213/64 , C07D401/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/08 , C07D491/107 , C07D498/08
Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.
-
-